NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
NGM Biopharmaceuticals, Inc. (NGM)
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
--Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key non-invasive biomarkers of metabolism, inflammation and fibrosis, with favorable tolerability profile -- -- Full 24-week 1 mg Cohort 4 data, including biopsy assessments, anticipated in Q1 2020 -- -- Company to host conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) -- SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced positive preliminary results from a pre-specified interim analysis of the aldafermin 1 mg 24-week Cohort 4, which is the final cohort of an adaptive Phase 2 study evaluating the efficacy, safety and tolerability of aldafermin (formerly NGM282) in patients with biopsy-co
Show less
Read more
Impact Snapshot
Event Time:
NGM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGM alerts
High impacting NGM Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NGM
News
- NGM Bio Announces Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- NGM Bio Announces Closing of Tender OfferGlobeNewswire
- Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law FirmGlobeNewswire
- IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire
- INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire
NGM
Earnings
- 3/11/24 - Beat
NGM
Sec Filings
- 4/5/24 - Form 25-NSE
- 4/5/24 - Form SC
- 4/5/24 - Form S-8
- NGM's page on the SEC website